Cortex’ Clinical Hold On CX717 Lifted By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The company may resume clinical trials of the compound, which it has studied for Alzheimer's disease and attention deficit/hyperactivity disorder.
You may also be interested in...
Cortex To Resume CX717 Alzheimer Study, Initiate ADHD Trial
Announcement comes after FDA approves a study protocol with higher doses of the Ampakine compound.
Cortex To Resume CX717 Alzheimer Study, Initiate ADHD Trial
Announcement comes after FDA approves a study protocol with higher doses of the Ampakine compound.
Cortex To Pursue CX717 In Alzheimer's Under FDA Dosing Restrictions
The company will not pursue an ADHD indication until further toxicological data show an increased safety margin for higher doses.